What does this research mean for the field?

Sugammadex was not associated with a significantly increased risk of pulmonary, cardiovascular, or mortality outcomes compared to neostigmine in severe CKD patients. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to compare short- and immediate-term outcomes of sugammadex and neostigmine in patients with severe chronic kidney disease during surgery.

February 9, 2026Open Access

Short- and immediate-term outcomes after sugammadex versus neostigmine in patients with severe chronic kidney disease: A retrospective cohort study

Key Result

Sugammadex did not increase pulmonary, cardiovascular, or mortality risks compared with neostigmine in severe CKD patients undergoing elective gastrointestinal surgery.

Key Points

This research aims to compare short- and immediate-term outcomes of sugammadex and neostigmine in patients with severe chronic kidney disease during surgery.
Retrospective cohort design
Patients with severe chronic kidney disease
Comparison between sugammadex and neostigmine
Outcomes measured included pulmonary, cardiovascular, and mortality events
No significant increase in pulmonary outcomes associated with sugammadex
No significant increase in cardiovascular outcomes associated with sugammadex
No significant increase in mortality outcomes associated with sugammadex compared to neostigmine

Structured PICO

Does sugammadex reduce the risk of pulmonary, cardiovascular, or mortality outcomes compared to neostigmine in patients with severe CKD having elective gastrointestinal surgery?

Population

Patients with severe chronic kidney disease (CKD) having elective gastrointestinal surgery

Intervention

Sugammadex

Comparator

Neostigmine

Outcome

Risk of pulmonary, cardiovascular, or mortality outcomeshard clinical

In patients with severe CKD undergoing elective GI surgery, sugammadex does not significantly increase short-term pulmonary, cardiovascular, or mortality risks compared to neostigmine.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Sugammadex was not associated with a significantly increased risk of pulmonary, cardiovascular, or mortality outcomes compared with neostigmine in patients with severe CKD having elective gastrointestinal surgery. Given the potential residual confounding by unmeasured factors such as surgical complexity, randomized controlled trials are needed to confirm these findings.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper